Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05214963 · ClinicalTrials.gov registry record · NA
Noninvasive Peripheral Nerve Stimulation for Medication-Naive and Medication-Refractory RLS
A NA study, sponsored by Noctrix Health.
- Completed
- Registry status
- NA
- Development phase
- 58
- Enrollment target
NCT05214963 is a NA study that has completed, run by Noctrix Health. The registered enrollment target is 58 participants.
The verdict
NCT05214963, a NA study, has completed, sponsored by Noctrix Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
Study Summary
Prospective multi-site randomized sham-controlled study evaluating tolerability and efficacy of noninvasive peripheral nerve stimulation (NPNS) for patients with moderate-severe primary Restless Legs Syndrome (RLS) who are either medication-naive or medication-refractory.
Interventions
- DEVICE NTX100 Neuromodulation System - Active
- DEVICE NTX100 Neuromodulation System - Sham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2022-03-08 |
| Est. Completion | 2023-10-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05214963
The ClinicalTrials.gov registry entry for NCT05214963 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Noctrix Health, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NTX100 Neuromodulation System - Active is the first listed.
NCT05214963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05214963 about?
NCT05214963 is a clinical study titled "Noninvasive Peripheral Nerve Stimulation for Medication-Naive and Medication-Refractory RLS". Prospective multi-site randomized sham-controlled study evaluating tolerability and efficacy of noninvasive peripheral nerve stimulation (NPNS) for patients with moderate-severe primary Restless Legs Syndrome (RLS) who are either medication-naive or medication-refractory.
What is the current status of trial NCT05214963?
This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2022-03-08. Estimated completion is 2023-10-24.
What interventions are being tested in trial NCT05214963?
The interventions under investigation include: NTX100 Neuromodulation System - Active (DEVICE), NTX100 Neuromodulation System - Sham (DEVICE).
Who is sponsoring clinical trial NCT05214963?
This trial is sponsored by Noctrix Health, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.